DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cixutumumab
Cixutumumab
HER2 Inhibition in Gastro-Oesophageal Cancer: a Review Drawing on Lessons Learned from Breast Cancer
Or Ramucirumab (IMC-1121B) Plus Mitoxantrone and Prednisone in Men with Metastatic Docetaxel-Pretreated Castration-Resistant Prostate Cancer
Therapeutic Targeting of the IGF Axis
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
Insulin-Like Growth Factor Pathway and the Thyroid
The Two Tontti Tudiul Lui Hi Ha Unit
Dual Inhibition of IGF1R and ER Enhances Response to Trastuzumab in HER2 Positive Breast Cancer Cells
(12) Patent Application Publication (10) Pub. No.: US 2014/0228233 A1 Pawlowski Et Al
Development and Preclinical Evaluation of Cixutumumab Drug
A Phase I/II Study of Erlotinib in Combination with the Anti
A Biomarker-Integrated Study in Patients with Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting
(INN) for Biological and Biotechnological Substances
Research Advances of Secretory Proteins in Malignant Tumors
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's
Integrative Meta-Analysis Identifies Microrna-Regulated Networks in Infantile Hemangioma Natália Bertoni, Lied M
Stembook 2018.Pdf
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Original Article Immuno-PET Imaging of VEGFR-2 Expression in Prostate Cancer with 89Zr-Labeled Ramucirumab
Top View
(INN) for Biological and Biotechnological Substances
Ramucirumab and GSK1838705A Enhance the Inhibitory Effects Of
Report on the Deliberation Results March 10, 2015 Evaluation And
HHS Public Access Author Manuscript
HER2-Positive Advanced Breast Cancer: Optimizing Patient Outcomes and Opportunities for Drug Development
Electrolyte Disorders Associated with the Use of Anticancer Drugs
Akt/Mtor Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–Like Growth Factor I Receptor Monoclonal Antibody
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
| Hao Hata Kata Tai Mit on a Man Taiwan Ta Material
Pancreatic Adenocarcinoma
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
This Is an Author Produced Version of a Paper Published in Current Drug Targets
Management of Recurrent Or Refractory Ewing Sarcoma: a Systematic Review of Phase II Clinical Trials in the Last 15 Years
WO 2018/183580 Al 04 October 2018 (04.10.2018) W !P O PCT
(IGF-1R) Antibody Cixutumumab Combined with the Mtor Inhibitor Temsirolimus in Patients with Metastatic Adrenocortical Carcinoma
Anti-IGF-1R Monoclonal Antibody
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Assessment of the Evolution of Cancer Treatment Therapies
IGF-1R/Mtor Targeted Therapy for Ewing Sarcoma: a Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma
In Children with Recurrent Solid Tumors: a Children's Oncology Group Phase I Consortium Report Maryam Fouladi1, John P
Combination Therapy Approaches to Target Insulin-Like Growth Factor Receptor Signaling in Breast Cancer
THERAPY CODES 4-Factor Concentrate F014 5A2A F017
Combining Targeted Therapeutics in the Era of Precision Medicine
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Patterns in Target-Directed Breast Cancer Research
The Effects of Metformin on Pancreatic Cancer Metabolism
That Are Not Cl Ementi
(2006.01) C07d 413/14
Effects on Cancer Therapy
New Data from Lilly Oncology Pipeline to Be Presented at ASCO 2010
Teprotumumab: the Dawn of Therapies in Moderate-To-Severe Thyroid-Associated Ophthalmopathy
Role of Mtor Inhibition in Preventing Resistance and Restoring Sensitivity to Hormone-Targeted and HER2-Targeted Therapies in Breast Cancer Ingrid Mayer, MD
Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease
Emerging Therapeutic Approaches in the Management of Metastatic Castration-Resistant Prostate Cancer
Earnings Presentation
Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors
Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
The Insulin-Like Growth Factor-I Receptor and Its Role in Thyroid- Associated Ophthalmopathy
Targeting Obesity-Related Dysfunction in Hormonally Driven Cancers
IGF1 Receptor and Thyroid-Associated Ophthalmopathy
Downloads/ Biologicsbloodvaccines/Guidancecomplianceregulatoryinformation/ Guidances/Vaccines/Ucm278673.Pdf]
The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis
Earnings Presentation
Targeting Mtor and Metabolism in Cancer: Lessons and Innovations
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Downloaded from Bioscientifica.Com at 10/01/2021 06:50:56AM Via Free Access Research a Dasari Et Al
Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
Do Thymic Malignancies Respond to Target Therapies? Interact Cardiovasc Thorac Surg 2015;20:855–9
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al